Roche delivered another strong quarter – group sales up by 7% at CER – pharma up 7% and diagnostics up 6%. New launches have been able to offset the impact of biosimilar competition for the bestsellers in Europe. The US continued to be the main contributor, while Europe the worst. The outlook for 2018 was retained – sales and core EPS growth in mid single-digit. The coming quarters will see biosimilars making their way in the US, posing a massive risk.
23 Oct 2018
Magnificent ‘seven’ again as borrowed time nears an end
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Magnificent ‘seven’ again as borrowed time nears an end
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
23 Oct 2018 -
Author:
Kamla Singh -
Pages:
3
Roche delivered another strong quarter – group sales up by 7% at CER – pharma up 7% and diagnostics up 6%. New launches have been able to offset the impact of biosimilar competition for the bestsellers in Europe. The US continued to be the main contributor, while Europe the worst. The outlook for 2018 was retained – sales and core EPS growth in mid single-digit. The coming quarters will see biosimilars making their way in the US, posing a massive risk.